BlackRock’s VanEck Pharmaceutical ETF PPH Stock Holding History

BlackRock’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$19K	Buy	+174	New	+$19.4K	﹤0.01%	5486

Other funds holding PPH

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $64.4B AUM 36.06% 1-Year Est. Return

J. Safra Asset Management New York $2.3B AUM 21.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.59B AUM 27.25% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Adamsbrown Wealth Consultants Wichita, Kansas $548M AUM 16.52% 1-Year Est. Return

Miller Investment Management West Conshohocken, Pennsylvania $1.13B AUM 13.3% 1-Year Est. Return

BlackRock's PPH Position: Q3 2026 in Review

BlackRock opened a new position in VanEck Pharmaceutical ETF (PPH) in Q3 2026: 174 shares worth $19K. The stake represents ﹤0.01% of the portfolio and ranks #5486 among its holdings.

124 funds tracked by Wall St. Rank hold PPH as of Q3 2026.

BlackRock held 174 shares of VanEck Pharmaceutical ETF worth $19K as of Q3 2026.
VanEck Pharmaceutical ETF was a new BlackRock position in Q3 2026.
VanEck Pharmaceutical ETF made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #5486 holding.
124 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.